ClinicalTrials.gg
CompletedNCT06978699XH-S003-II-101Updated Nov 18, 2026

A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 2 interventional study of XH-S003 Capsule and XH-S003 Capsule in PNH - Paroxysmal Nocturnal Hemoglobinuria, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

Updated Nov 18, 2026Now CompletedStart date moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 51 studies in Hemoglobinuria, Paroxysmal with a site in China — 20 open to participants now, 28 under way, 11 of them phase 3. Hemoglobinuria, Paroxysmal · China.

Enrollment
32nd of 47
26 · median 40
Started
2025
with 11 others
Phase 2
13 of 51
3 open now
Registered
35th of 51
by date
Lead sponsor
4 of 51
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Among the 51 studies in Hemoglobinuria, Paroxysmal with a site in China, this one is the 32nd largest by enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2025, is one of 13 in phase 2, and was the 35th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 48 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

20 of the 51 studies in Hemoglobinuria, Paroxysmal with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Hemoglobinuria, Paroxysmal studies recruiting now, 13 (45%) set no upper age limit and 11 (38%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Hemoglobinuria, Paroxysmal with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally according to protocol.

03

Conditions studied

  • PNH - Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Male or female with aged ≥18 years at screening; 2. Weight ≥40 kg and ≥18 kg/m2 at screening; 3.Participants diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) based on the PNH diagnostic criteria in the Chinese "Guidelines for the Diagnosis and Therapy of Paroxysmal Nocturnal Hemoglobinuria" (2024 edition), with red blood cell or neutrophil clone levels >10% detected by flow cytometry within 6 months prior to screening or during screening; 4. The PNH patients included in the study consist of two groups: Group 1: Patients who have not previously received any complement inhibitor therapy or have not received complement inhibitor therapy for at least 3 months prior to randomization (or within 5 drug half-lives, whichever is longer); Group 2: Patients who have been stably treated with anti-C5 antibody for 6 months prior to randomization;; 5.For patients in Group 1, at least two tests during the screening period (2 to 8 weeks apart) show LDH > 1.5× (multiple tests are allowed during the screening period); 6. meets one of the following conditions: (1) Hb concentration \< 100 g/L at the first screening visit, and the patient received red blood cell transfusion therapy for PNH-related anemia during the screening period; (2) The average Hb concentration of two tests during the screening period is \<100 g/L (these two tests must be 2 to 8 weeks apart. Multiple Hb tests are allowed during the screening period); 7. Vaccination against Neisseria meningitidis and Streptococcus pneumoniae must be completed before the first drug administration. If the patient has not been vaccinated previously or requires booster vaccination (according to local vaccination policies), vaccination should be completed at least 2 weeks before the first drug administration. If the first drug administration must occur within 2 weeks after vaccination, prophylactic antibiotic therapy should be used until at least 2 weeks after vaccination.; 8.Participants of commit to having no plans for pregnancy or sperm/egg donation from screening until 1 month (female participants) or 3 months (male participants) after the last dose and voluntarily take effective physical methods (including partners); 9. Have a detailed understanding of the nature, significance, possible benefits, potential inconveniences, and potential risks of the trial, and voluntarily participate in this clinical trial; Able to communicate well with the investigators and comply with the requirements of the entire study; Signed a written form.

Exclusion criteria

Exclusion Criteria:

  1. With laboratory evidence of bone marrow failure during screening (reticulocyte count \< 100 × 109/L, or count \< 30 × 109/L, or \< 0.5 × 109/L); Received acute treatment (such as platelet transfusion, granulocyte colony-stimulating factor) for thrombocytopenia or neutropenia within 30 days before screening;
  2. Participants receiving other therapies before screening that have not reached the following stable treatment durations:

    • Erythropoietin or for at least 8 weeks
    • systemic for at least 4 weeks
    • Iron, vitamin B12, or folic acid supplementation for at least 4 weeks
    • Anticoagulants: Vitamin K antagonists (such as warfarin) used for at least 4 weeks with a stable (INR) (as determined by the investigator), low molecular weight heparin, oral anticoagulants such as aspirin, rivaroxaban, apixaban, etc., for at least 4 weeks;
    • Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for at least 8 weeks;
    • Androgens for at least 4 weeks;
  3. History of malignant tumors of any organ or system within 5 years before screening (except local basal cell carcinoma of the skin or carcinoma in situ of the cervix), regardless of whether treatment was received and whether there is evidence of local recurrence or ;
  4. History of bone marrow/hematopoietic stem cell or solid organ transplantation (such as heart, lung, kidney, liver);
  5. History of splenectomy or planned surgery during the study period;
  6. Significantly abnormal liver function at screening: any parameter of , γ-glutamyl transpeptidase (GGT), or alkaline phosphatase (ALP) > 3 × ;
  7. (HIV) infection (HIV antibody positive), active syphilis infection, virus infection (hepatitis B surface antigen positive), active virus infection, or active tuberculosis infection at screening;
  8. Concurrent systemic critical diseases, including but not limited to: advanced heart disease (such as [NYHA] Class IV), severe lung disease (such as severe pulmonary hypertension [WHO class IV]), active hepatitis, severe kidney disease (estimated [eGFR] \< 30 mL/min/1.73 m2 or chronic kidney disease [CKD] stage 4 or dialysis patients), unstable thrombosis, active gastrointestinal hemorrhage, other blood disorders (such as chronic anemia unrelated to PNH), which are deemed unsuitable for study participation by the investigator;
  9. Known or suspected by investigators to have immunodeficiency diseases or hereditary complement deficiency;
  10. History of Neisseria meningitidis infection; 11. Individuals with chronic active or recurrent infections within 1 year prior to screening, deemed unsuitable for participation in this study by the investigator, such as liver abscess or pyelonephritis;

12. Individuals with systemic active bacterial, viral (including COVID-19), or fungal infections within 2 weeks prior to the first dose; or with an axillary body temperature >38°C within 7 days prior to the first dose; 13. Individuals suspected or confirmed to be allergic to components similar to the drug or any component of the investigational drug; 14. Pregnant or lactating women, or those with a positive pregnancy test; 15. Individuals with a history of drug abuse or substance abuse; 16. Individuals with a history of alcoholism within 6 months prior to screening (average weekly consumption of ≥14 units of alcohol: 1 unit = 285 mL of beer; or 25 mL of spirits; or 125 mL of wine); 17. Individuals who participated in other clinical trials involving investigational drugs within 30 days prior to screening (or still within 5 half-lives of the drug, whichever is longer, excluding C5 complement inhibitors for group 2) or medical device clinical trials, or those planning to participate in other clinical trials during the study period, or those deemed by the investigator to have residual effects; 18. Individuals assessed by the investigator to have diseases or medical conditions that could affect drug absorption, distribution, metabolism, and excretion, or that could reduce compliance or increase the risk to the subject, such as a history of severe gastrointestinal disease, major gastrointestinal surgery, or difficulty in taking medication; or individuals who may be unable to complete the study for other reasons, or other situations where the investigator deems participation in the study inappropriate.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    High Dose

    XH-S003 Capsule, Administered orally once daily, 125mg, 12-week continuous dosing period.

    Drug: XH-S003 Capsule

  • Experimental
    Medium Dose

    XH-S003 Capsule, Administered orally once daily, 100mg, 12-week continuous dosing period.

    Drug: XH-S003 Capsule

  • Experimental
    Low Dose

    XH-S003 Capsule, Administered orally once daily,50mg, 12-week continuous dosing period.

    Drug: XH-S003 Capsule

Interventions

  • DrugXH-S003 Capsule

    XH-S003 Capsule, Administered orally once daily, 125mg

  • DrugXH-S003 Capsule

    XH-S003 Capsule, Administered orally once daily, 100mg

  • DrugXH-S003 Capsule

    XH-S003 Capsule, Administered orally once daily, 50mg

06

What researchers measure

Primary outcomes

  1. Changes of hemoglobin compared with baseline

    Time frame: 12 weeks from baseline

Secondary outcomes

  1. Proportion of participants with an increase in Hb ≥20g/L compared with baseline (without RBC transfusion);

    Time frame: 12 weeks from baseline

  2. Changes in Indirect Bilirubin compared to baseline;

    Time frame: 12 weeks from baseline

  3. Changes in reticulocyte counts compared to baseline;

    Time frame: 12 weeks from baseline

  4. Proportion of participants with Hb ≥120g/L (without RBC transfusion);

    Time frame: 12 weeks

  5. Changes in LDH compared with baseline

    Time frame: 12 weeks from baseline

  6. Proportion of participants with LDH ≤1.5 ULN

    Time frame: 12 weeks

  7. Proportion of participants without RBC transfusion

    Time frame: 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jan 2026, 8 months.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 8 months is below that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Apr 2025 → May 2025, primary completion Aug 2025 → Jan 2026 and completion Oct 2026 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 18, 2025
StartActual
May 21, 2025was Apr 2025
Primary completionActual
Jan 21, 2026was Aug 2025
CompletionActual
Jan 21, 2026was Oct 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 18, 2026
Start date
Apr 30, 2025→May 21, 2025
Nov 18, 2026
Primary completion
Aug 30, 2025→Jan 21, 2026 (actual)
Nov 18, 2026
Study completion
Oct 30, 2026→Jan 21, 2026 (actual)
Nov 18, 2026
Enrollment
24 (estimated)→26 (actual)
Nov 18, 2026
Eligibility
1 inclusion criterion added, 7 removed; 6 exclusion criteria edited, 11 added, 3 removed
What changed in the criteria
Inclusion criteria
  • RemovedMale or female with aged ≥18 years old;
  • RemovedWeight ≥40 kg and BMI≥18 kg/m2 ;
  • RemovedDiagnosed with PNH: with red blood cell or granulocyte clone levels >10% detected by flow cytopy within 6 months prior to screening or during screening;
  • RemovedPatients who have not previously received any complement inhibitor therayp;
  • RemovedLDH > 1.5×ULN detected two times during the screening period (interval of 2 to 8 weeks);
  • RemovedHb meets one of the following conditions: (1) Hb <100 g/L at the first screening visit, and subjects receive RBC transfusion because of PNH-related anemia during the screening period; (2) The average Hb of two tests during the screening period <100 g/L (interval of 2~8 weeks);
  • RemovedVaccination against Neisseria meningitidis and Streptococcus pneumoniae before the first administration. If the subject has not been vaccinated previously or requires booster vaccination (according to local vaccination policies), vaccination must be administered at least 2 weeks before the first administration. If the first administration must begin less than 2 weeks after vaccination, preventive antibiotic treatment must begin at least 2 weeks after vaccination;
  • Added1. Male or female with aged ≥18 years at screening; 2. Weight ≥40 kg and BMI≥18 kg/m2 at screening; 3.Participants diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) based on the PNH diagnostic criteria in the Chinese "Guidelines for the Diagnosis and Therapy of Paroxysmal Nocturnal Hemoglobinuria" (2024 edition), with red blood cell or neutrophil clone levels >10% detected by flow cytometry within 6 months prior to screening or during screening; 4. The PNH patients included in the study consist of two groups: Group 1: Patients who have not previously received any complement inhibitor therapy or have not received complement inhibitor therapy for at least 3 months prior to randomization (or within 5 drug half-lives, whichever is longer); Group 2: Patients who have been stably treated with anti-C5 antibody for 6 months prior to randomization;; 5.For patients in Group 1, at least two tests during the screening period (2 to 8 weeks apart) show LDH > 1.5×ULN (multiple tests are allowed during the screening period); 6.Hb meets one of the following conditions: (1) Hb concentration < 100 g/L at the first screening visit, and the patient received red blood cell transfusion therapy for PNH-related anemia during the screening period; (2) The average Hb concentration of two tests during the screening period is <100 g/L (these two tests must be 2 to 8 weeks apart. Multiple Hb tests are allowed during the screening period); 7. Vaccination against Neisseria meningitidis and Streptococ…
Exclusion criteria
  • EditedSubjects withWith laboratory evidence of bone marrow failure during the screening period (reticulocyte count < 100 × 109/L, or platelet count < 30 × 109/L, or neutrophil count < 0.5 × 109/L); Received acute treatment (such as platelet transfusion, granulocyte colony-stimulating factor) for thrombocytopenia or neutropenia within 30 days before screening;
  • EditedSubjectsParticipants receiving other therapies prior tobefore screening whothat have not achievedreached the following stable treatment durations:
  • RemovedErythropoietin or immunosuppressants for at least 8 weeks; • Systemic corticosteroids for at least 4 weeks; • Iron supplements, vitamin B12, or folic acid for at least 4 weeks; • Anticoagulants: Vitamin K antagonists for at least 4 weeks with stable international normalized ratio (INR) (as determined by the investigator), low molecular weight heparin for at least 4 weeks; • Hypoxic-inducing factor prolyl hydroxylase inhibitors (HIF-PHI) for at least 8 weeks; • Androgens for at least 4 weeks;
  • AddedErythropoietin or Immunosuppressants for at least 8 weeks
  • Addedsystemic corticosteroids for at least 4 weeks
  • AddedIron, vitamin B12, or folic acid supplementation for at least 4 weeks
  • AddedAnticoagulants: Vitamin K antagonists (such as warfarin) used for at least 4 weeks with a stable international normalized ratio (INR) (as determined by the investigator), low molecular weight heparin, oral anticoagulants such as aspirin, rivaroxaban, apixaban, etc., for at least 4 weeks;
  • AddedHypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for at least 8 weeks;
  • AddedAndrogens for at least 4 weeks;
  • AddedHistory of malignant tumors of any organ or system within 5 years before screening (except local basal cell carcinoma of the skin or carcinoma in situ of the cervix), regardless of whether treatment was received and whether there is evidence of local recurrence or metastasis;
  • EditedA historyHistory of bone marrow/hematopoietic stem cell or solid organ transplantation (such as heart, lung, kidney, liver);
  • AddedHistory of splenectomy or planned surgery during the study period;
  • EditedAlanine aminotransferase (Significantly abnormal liver function at screening: any parameter of ALT), γ-glutamyl transpeptidase (GGT), or alkaline phosphatase (ALP) > 3 × ULN at screening; - Positive HIV antibody, active syphilis infection, positive HBsAg, active HCV infection, or active tuberculosis infection at screening;
  • AddedHuman immunodeficiency virus (HIV) infection (HIV antibody positive), active syphilis infection, hepatitis B virus infection (hepatitis B surface antigen positive), active hepatitis C virus infection, or active tuberculosis infection at screening;
  • AddedConcurrent systemic critical diseases, including but not limited to: advanced heart disease (such as New York Heart Association [NYHA] Class IV), severe lung disease (such as severe pulmonary hypertension [WHO class IV]), active hepatitis, severe kidney disease (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2 or chronic kidney disease [CKD] stage 4 or dialysis patients), unstable thrombosis, active gastrointestinal hemorrhage, other blood disorders (such as chronic anemia unrelated to PNH), which are deemed unsuitable for study participation by the investigator;
  • EditedKnown or suspected by investigators to have immunodeficiency diseases or hereditary complement deficiency at screening;
  • RemovedA history of Neisseria meningitidis infection;
  • EditedSubjectsHistory of Neisseria meningitidis infection; 11. Individuals with chronic active or recurrent infections within 1 year prior to screening, deemed unsuitable for participation in this study by the investigator, such as liver abscess or pyelonephritis;
  • RemovedSubjects with systemic active bacterial, viral (including COVID-19), or fungal infections within 2 weeks prior to the first administration; subjects with body temperature >38°C within 7 days prior to the first administration;
  • Added12. Individuals with systemic active bacterial, viral (including COVID-19), or fungal infections within 2 weeks prior to the first dose; or with an axillary body temperature >38°C within 7 days prior to the first dose; 13. Individuals suspected or confirmed to be allergic to components similar to the investigational drug or any component of the investigational drug; 14. Pregnant or lactating women, or those with a positive pregnancy test; 15. Individuals with a history of drug abuse or substance abuse; 16. Individuals with a history of alcoholism within 6 months prior to screening (average weekly consumption of ≥14 units of alcohol: 1 unit = 285 mL of beer; or 25 mL of spirits; or 125 mL of wine); 17. Individuals who participated in other clinical trials involving investigational drugs within 30 days prior to screening (or still within 5 half-lives of the drug, whichever is longer, excluding C5 complement inhibitors for group 2) or medical device clinical trials, or those planning to participate in other clinical trials during the study period, or those deemed by the investigator to have residual effects; 18. Individuals assessed by the investigator to have diseases or medical conditions that could affect drug absorption, distribution, metabolism, and excretion, or that could reduce compliance or increase the risk to the subject, such as a history of severe gastrointestinal disease, major gastrointestinal surgery, or difficulty in taking medication; or individuals who may be…
Nov 18, 2026
Interventions
Added Drug: XH-S003 Capsule. Arms added: High Dose·Medium Dose·Low Dose; arms removed: Dose 1·Dose 2·Dose 3
Nov 18, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameChanges of hemoglobin compared with baseline8 weeks → 12 weeks from baseline
  • DescriptionChanges of hemoglobin compared with baseline: how it is measured was reworded
Nov 18, 2026
Secondary outcomes
2 edited, 3 time frame changed, 2 added, 3 description edited
What changed in the outcomes
  • EditedProportion of subjectsparticipants with an increase in Hb ≥20g/L compared with baseline (without RBC transfusion);Time frame: 8 weeks → 12 weeks from baseline
  • EditedProportion of subjectsparticipants without RBC transfusionTime frame: 8 weeks → 12 weeks
  • AddedProportion of participants with Hb ≥120g/L (without RBC transfusion);Time frame: 12 weeks
  • AddedProportion of participants with LDH ≤1.5 ULNTime frame: 12 weeks
  • Time frameChanges in Indirect Bilirubin compared to baseline;8 weeks → 12 weeks from baseline
  • Time frameChanges in reticulocyte counts compared to baseline;8 weeks → 12 weeks from baseline
  • Time frameChanges in LDH compared with baseline8 weeks → 12 weeks from baseline
  • DescriptionChanges in Indirect Bilirubin compared to baseline;: how it is measured was reworded
  • DescriptionChanges in LDH compared with baseline: how it is measured was reworded
  • DescriptionChanges in reticulocyte counts compared to baseline;: how it is measured was reworded
Nov 18, 2026
Sponsor
S-INFINITY Pharmaceuticals Co., Ltd→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Completed
    Start date Apr 30, 2025→May 21, 2025
    Primary completion Aug 30, 2025→Jan 21, 2026 (now actual)
    Study completion Oct 30, 2026→Jan 21, 2026 (now actual)
    Enrollment 24 (estimated)→26 (actual)
    Eligibility 1 inclusion criterion added, 7 removed; 6 exclusion criteria edited, 11 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedMale or female with aged ≥18 years old;
    • RemovedWeight ≥40 kg and BMI≥18 kg/m2 ;
    • RemovedDiagnosed with PNH: with red blood cell or granulocyte clone levels >10% detected by flow cytopy within 6 months prior to screening or during screening;
    • RemovedPatients who have not previously received any complement inhibitor therayp;
    • RemovedLDH > 1.5×ULN detected two times during the screening period (interval of 2 to 8 weeks);
    • RemovedHb meets one of the following conditions: (1) Hb <100 g/L at the first screening visit, and subjects receive RBC transfusion because of PNH-related anemia during the screening period; (2) The average Hb of two tests during the screening period <100 g/L (interval of 2~8 weeks);
    • RemovedVaccination against Neisseria meningitidis and Streptococcus pneumoniae before the first administration. If the subject has not been vaccinated previously or requires booster vaccination (according to local vaccination policies), vaccination must be administered at least 2 weeks before the first administration. If the first administration must begin less than 2 weeks after vaccination, preventive antibiotic treatment must begin at least 2 weeks after vaccination;
    • Added1. Male or female with aged ≥18 years at screening; 2. Weight ≥40 kg and BMI≥18 kg/m2 at screening; 3.Participants diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) based on the PNH diagnostic criteria in the Chinese "Guidelines for the Diagnosis and Therapy of Paroxysmal Nocturnal Hemoglobinuria" (2024 edition), with red blood cell or neutrophil clone levels >10% detected by flow cytometry within 6 months prior to screening or during screening; 4. The PNH patients included in the study consist of two groups: Group 1: Patients who have not previously received any complement inhibitor therapy or have not received complement inhibitor therapy for at least 3 months prior to randomization (or within 5 drug half-lives, whichever is longer); Group 2: Patients who have been stably treated with anti-C5 antibody for 6 months prior to randomization;; 5.For patients in Group 1, at least two tests during the screening period (2 to 8 weeks apart) show LDH > 1.5×ULN (multiple tests are allowed during the screening period); 6.Hb meets one of the following conditions: (1) Hb concentration < 100 g/L at the first screening visit, and the patient received red blood cell transfusion therapy for PNH-related anemia during the screening period; (2) The average Hb concentration of two tests during the screening period is <100 g/L (these two tests must be 2 to 8 weeks apart. Multiple Hb tests are allowed during the screening period); 7. Vaccination against Neisseria meningitidis and Streptococ…
    Exclusion criteria
    • EditedSubjects withWith laboratory evidence of bone marrow failure during the screening period (reticulocyte count < 100 × 109/L, or platelet count < 30 × 109/L, or neutrophil count < 0.5 × 109/L); Received acute treatment (such as platelet transfusion, granulocyte colony-stimulating factor) for thrombocytopenia or neutropenia within 30 days before screening;
    • EditedSubjectsParticipants receiving other therapies prior tobefore screening whothat have not achievedreached the following stable treatment durations:
    • RemovedErythropoietin or immunosuppressants for at least 8 weeks; • Systemic corticosteroids for at least 4 weeks; • Iron supplements, vitamin B12, or folic acid for at least 4 weeks; • Anticoagulants: Vitamin K antagonists for at least 4 weeks with stable international normalized ratio (INR) (as determined by the investigator), low molecular weight heparin for at least 4 weeks; • Hypoxic-inducing factor prolyl hydroxylase inhibitors (HIF-PHI) for at least 8 weeks; • Androgens for at least 4 weeks;
    • AddedErythropoietin or Immunosuppressants for at least 8 weeks
    • Addedsystemic corticosteroids for at least 4 weeks
    • AddedIron, vitamin B12, or folic acid supplementation for at least 4 weeks
    • AddedAnticoagulants: Vitamin K antagonists (such as warfarin) used for at least 4 weeks with a stable international normalized ratio (INR) (as determined by the investigator), low molecular weight heparin, oral anticoagulants such as aspirin, rivaroxaban, apixaban, etc., for at least 4 weeks;
    • AddedHypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for at least 8 weeks;
    • AddedAndrogens for at least 4 weeks;
    • AddedHistory of malignant tumors of any organ or system within 5 years before screening (except local basal cell carcinoma of the skin or carcinoma in situ of the cervix), regardless of whether treatment was received and whether there is evidence of local recurrence or metastasis;
    • EditedA historyHistory of bone marrow/hematopoietic stem cell or solid organ transplantation (such as heart, lung, kidney, liver);
    • AddedHistory of splenectomy or planned surgery during the study period;
    • EditedAlanine aminotransferase (Significantly abnormal liver function at screening: any parameter of ALT), γ-glutamyl transpeptidase (GGT), or alkaline phosphatase (ALP) > 3 × ULN at screening; - Positive HIV antibody, active syphilis infection, positive HBsAg, active HCV infection, or active tuberculosis infection at screening;
    • AddedHuman immunodeficiency virus (HIV) infection (HIV antibody positive), active syphilis infection, hepatitis B virus infection (hepatitis B surface antigen positive), active hepatitis C virus infection, or active tuberculosis infection at screening;
    • AddedConcurrent systemic critical diseases, including but not limited to: advanced heart disease (such as New York Heart Association [NYHA] Class IV), severe lung disease (such as severe pulmonary hypertension [WHO class IV]), active hepatitis, severe kidney disease (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2 or chronic kidney disease [CKD] stage 4 or dialysis patients), unstable thrombosis, active gastrointestinal hemorrhage, other blood disorders (such as chronic anemia unrelated to PNH), which are deemed unsuitable for study participation by the investigator;
    • EditedKnown or suspected by investigators to have immunodeficiency diseases or hereditary complement deficiency at screening;
    • RemovedA history of Neisseria meningitidis infection;
    • EditedSubjectsHistory of Neisseria meningitidis infection; 11. Individuals with chronic active or recurrent infections within 1 year prior to screening, deemed unsuitable for participation in this study by the investigator, such as liver abscess or pyelonephritis;
    • RemovedSubjects with systemic active bacterial, viral (including COVID-19), or fungal infections within 2 weeks prior to the first administration; subjects with body temperature >38°C within 7 days prior to the first administration;
    • Added12. Individuals with systemic active bacterial, viral (including COVID-19), or fungal infections within 2 weeks prior to the first dose; or with an axillary body temperature >38°C within 7 days prior to the first dose; 13. Individuals suspected or confirmed to be allergic to components similar to the investigational drug or any component of the investigational drug; 14. Pregnant or lactating women, or those with a positive pregnancy test; 15. Individuals with a history of drug abuse or substance abuse; 16. Individuals with a history of alcoholism within 6 months prior to screening (average weekly consumption of ≥14 units of alcohol: 1 unit = 285 mL of beer; or 25 mL of spirits; or 125 mL of wine); 17. Individuals who participated in other clinical trials involving investigational drugs within 30 days prior to screening (or still within 5 half-lives of the drug, whichever is longer, excluding C5 complement inhibitors for group 2) or medical device clinical trials, or those planning to participate in other clinical trials during the study period, or those deemed by the investigator to have residual effects; 18. Individuals assessed by the investigator to have diseases or medical conditions that could affect drug absorption, distribution, metabolism, and excretion, or that could reduce compliance or increase the risk to the subject, such as a history of severe gastrointestinal disease, major gastrointestinal surgery, or difficulty in taking medication; or individuals who may be…
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameChanges of hemoglobin compared with baseline8 weeks → 12 weeks from baseline
    • DescriptionChanges of hemoglobin compared with baseline: how it is measured was reworded
    Secondary outcomes 2 edited, 3 time frame changed, 2 added, 3 description edited
    What changed in the outcomes
    • EditedProportion of subjectsparticipants with an increase in Hb ≥20g/L compared with baseline (without RBC transfusion);Time frame: 8 weeks → 12 weeks from baseline
    • EditedProportion of subjectsparticipants without RBC transfusionTime frame: 8 weeks → 12 weeks
    • AddedProportion of participants with Hb ≥120g/L (without RBC transfusion);Time frame: 12 weeks
    • AddedProportion of participants with LDH ≤1.5 ULNTime frame: 12 weeks
    • Time frameChanges in Indirect Bilirubin compared to baseline;8 weeks → 12 weeks from baseline
    • Time frameChanges in reticulocyte counts compared to baseline;8 weeks → 12 weeks from baseline
    • Time frameChanges in LDH compared with baseline8 weeks → 12 weeks from baseline
    • DescriptionChanges in Indirect Bilirubin compared to baseline;: how it is measured was reworded
    • DescriptionChanges in LDH compared with baseline: how it is measured was reworded
    • DescriptionChanges in reticulocyte counts compared to baseline;: how it is measured was reworded
    Interventions Added Drug: XH-S003 Capsule. Arms added: High Dose·Medium Dose·Low Dose; arms removed: Dose 1·Dose 2·Dose 3
    Sponsor S-INFINITY Pharmaceuticals Co., Ltd→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    + 5 other changes: identifiers, verification date, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06978699
Responsible party
Sponsor
First posted
May 18, 2025
Start date
May 21, 2025
Primary completion
Jan 21, 2026
Completion
Jan 21, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion